发明名称 THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS
摘要 Disclosed are tricyclic aryl thiophene derivatives and their salts as represented by the general formula (I) wherein: A represents an oxazole, oxadiazole, thiazole or thiadiazole moiety as defined herein; or A represents -CO-CH2CH2- or -CO-CH=CH-; R1 represents alkyl; R2 represents hydrogen, methyl or ethyl; R3 represents hydrogen; R4 represents methyl, ethyl, or methoxy; R6 represents methyl, ethyl or halogen; and R5 represents a substituent as defined herein. Of particular importance are the compounds 2-hydroxy-N-((2S)-2-hydroxy-3-{ 4-[5-(5-isobutyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-2,6-dimethyl-phenoxy} -propyl)-acetamide; N-((2S)-3-{ 2-ethyl-6-methyl-4-[5-(5-propyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-phenoxy} -2-hydroxy-propyl)-2-hydroxy-acetamide; (2R)-3-{ 2-ethyl-4-[5-(5-isobutyl-4-methyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl-6-methyl-phenoxy} -propane-1,2-diol; (2S)-3-{ 2-ethyl-4-[5-(5-isobutyl-4-methyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenoxy} -propane-1,2-diol; N-((2R)-3-{ 2-ethyl-4-[5-(5-isobutyl-4-methyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenoxy} -2-hydroxy-propyl)-2-hydroxy-acetamide and N-((2S)-3-{ 2-ethyl-4-[5-(5-isobutyl-4-methyl-thiophen-2-yl)-[1,3,4]oxadiazol-2-yl]-6-methyl-phenoxy} -2-hydroxy-propyl)-2-hydroxy-acetamide. Further disclosed is a pharmaceutical composition which comprises a compound as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveoretinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumour metastasis.
申请公布号 NZ575979(A) 申请公布日期 2012.02.24
申请号 NZ20070575979 申请日期 2007.07.10
申请人 ACTELION PHARMACEUTICALS LTD. 发明人 BOLLI, MARTIN;LEHMANN, DAVID;MATHYS, BORIS;MUELLER, CLAUS;NAYLER, OLIVER;STEINER, BEAT;VELKER, JORG
分类号 A61K31/381;A61P17/00;A61P37/00;C07D333/22;C07D413/04 主分类号 A61K31/381
代理机构 代理人
主权项
地址
您可能感兴趣的专利